Natalizumab Disease Interactions
There are 4 disease interactions with natalizumab:
Immunosuppressive agents (applies to natalizumab) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.
Immunosuppressive agents (applies to natalizumab) PML
Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.
Natalizumab (applies to natalizumab) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Postmarketing reports have associated the use of natalizumab with severe hepatic toxicity, including acute liver failure requiring transplant. Natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury and appropriate therapy should be instituted according to clinical guidelines.
Natalizumab (applies to natalizumab) meningitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Herpes Zoster Meningitis
Natalizumab increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. It is recommended to monitor patients receiving natalizumab for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, treatment should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.
Natalizumab drug interactions
There are 319 drug interactions with natalizumab
More about natalizumab
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 98 Reviews
- Drug class: selective immunosuppressants
Related treatment guides
Drug Interaction Classification
|No interaction information available.|